PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 52 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

8 February 2025

  1. (diff | hist) m 12:12 Peptide 4,933 +874 SurmountSurma (talk | contribs) state that overlay gas is used and name it [rollback]
  2. (diff | hist) 07:22 Tirzepatide 6,234 +845 IcodecIndra (talk | contribs) expand §Adverse effects and tolerability [rollback]
  3. (diff | hist) 06:41 Shanghai Wibson Biotechnology 2,894 +692 UnderfillUna (talk | contribs) correct the other-designations row — those are trading variants, not subsidiaries [rollback]
  4. (diff | hist) 05:01 Guangzhou JEEP Biotechnology 8,821 +494 COA_Colwyn (talk | contribs) expand the product-scope row in the infobox [rollback]
  5. (diff | hist) 04:29 CagriSema 3,776 +787 Hedgerow_Hal (talk | contribs) add the excipient list from the labelling [rollback]

7 February 2025

  1. (diff | hist) m 22:24 C-peptide 3,250 ±0 DiffWatchDov (talk | contribs) expand §Interpretation caveats [rollback]
  2. (diff | hist) m 21:16 Grey market 2,576 ±0 Areapercent_Ayo (talk | contribs) add the data-logger point: an unlogged shipment has no excursion record [rollback]
  3. (diff | hist) 18:36 Chinese Peptide Company 9,245 +93 BatchNumberBede (talk | contribs) add the registered legal name exactly as it appears in the registry record [rollback]
  4. (diff | hist) m 17:24 Certificate of analysis 6,396 ±0 BetaCellBoyd (talk | contribs) add the chain-of-custody point to §Limitations [rollback]
  5. (diff | hist) m 16:47 Glucose-dependent insulinotropic polypeptide 6,686 +455 DPP4_Dagmar (talk | contribs) ce, tighten prose [rollback]
  6. (diff | hist) 14:08 Beyond-use date 10,475 +688 SyringeSybille (talk | contribs) add the sharps-disposal cross-link [rollback]
  7. (diff | hist) 13:29 Mass spectrometry 4,327 ±0 KarlFischerKit (talk | contribs) state that ultraviolet response is not uniform across impurities [rollback]
  8. (diff | hist) 13:24 Proglucagon 4,998 ±0 Chromatokid (talk | contribs) expand §Gene and transcript [rollback]
  9. (diff | hist) 08:20 Missed dose 4,123 +736 Chromatokid (talk | contribs) rm the individualised advice — the article describes, it does not instruct [rollback]
  10. (diff | hist) m 06:56 Liquid chromatography-mass spectrometry 3,451 +136 ReportReaderRilla (talk | contribs) expand §Quantification [rollback]
  11. (diff | hist) 04:21 Sterility testing 3,235 +150 AnalyticalAnnie (talk | contribs) typo [rollback]
  12. (diff | hist) 03:01 Incretin effect 5,425 +28 IncretinIvo (talk | contribs) expand §Mechanisms: GLP-1 and GIP [rollback]
  13. (diff | hist) m b 01:00 Fmoc chemistry 3,718 ±0 ArchiveBot (talk | contribs) bot: normalise temperature formatting [rollback]

6 February 2025

  1. (diff | hist) 20:03 Purity claim inflation 3,603 +536 LOD_Lorcan (talk | contribs) add the laboratory accreditation status, or say plainly that it is not stated [rollback]
  2. (diff | hist) 09:54 Peptide aggregation 3,901 +786 LeanMassLars (talk | contribs) add the detection wavelength [rollback]
  3. (diff | hist) 09:47 USP General Chapter 71 2,935 +681 GlossaryGleb (talk | contribs) convert a hard-coded date to the house format [rollback]
  4. (diff | hist) m 07:22 Dipeptidyl peptidase-4 5,763 ±0 BetaCellBoyd (talk | contribs) distinguish the active and total forms of the hormone throughout [rollback]
  5. (diff | hist) 04:26 Peptide supply chain 5,181 +1,005 IpamorelinIsold (talk | contribs) clarify that "cold chain" without a logger is a claim, not a record [rollback]
  6. (diff | hist) 01:41 Gastric emptying 4,636 ±0 CuriousCallum (talk | contribs) the glucose-dependence of the insulinotropic effect deserves its own sentence [rollback]

5 February 2025

  1. (diff | hist) 23:50 Amylin 3,956 +23 LiraLotte (talk | contribs) expand §Receptors [rollback]
  2. (diff | hist) 22:44 Cagrilintide 3,147 ±0 INN_Ingrid (talk | contribs) rm the equipotency claim — the cited paper does not make it [rollback]
  3. (diff | hist) 22:00 ISO 9001 3,129 ±0 UACR_Ulric (talk | contribs) add the citation for the regulatory action [rollback]
  4. (diff | hist) 18:11 Nantong Guangyuan Chemical 8,121 +83 CapitalisationCaz (talk | contribs) expand §Distribution and dispatch [rollback]
  5. (diff | hist) 10:01 Hunan Aslsen Technology 7,721 +1,429 BlankVialBo (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  6. (diff | hist) 09:39 Baseline laboratory panel 2,373 +36 BiosimilarBoaz (talk | contribs) convert the interval table to include both conventional and SI units [rollback]
  7. (diff | hist) m 09:39 Solid-phase peptide synthesis 4,279 ±0 DPP4_Dagmar (talk | contribs) add the stopper material, since it affects moisture ingress [rollback]
  8. (diff | hist) 08:16 Talk:Research use only 959 +122 DMF_Dermot (talk | contribs) /* "Not approved" versus "unapproved" */ reply
  9. (diff | hist) 05:29 Karl Fischer titration 6,559 +538 TechnicianTeal (talk | contribs) fix indentation in the source [rollback]
  10. (diff | hist) 04:59 Wuhan Wansheng Biotechnology 9,239 +27 AmylinAmos (talk | contribs) expand §External links [rollback]
  11. (diff | hist) m 04:40 Weight regain after discontinuation 3,696 +126 NauseaNoor (talk | contribs) add the note that titration exists partly to manage these effects [rollback]
  12. (diff | hist) m 04:31 Drug master file 2,265 +37 Chromatokid (talk | contribs) add the effective date to the regulatory table [rollback]

4 February 2025

  1. (diff | hist) m 23:25 Good manufacturing practice 3,548 +218 FiveOhThreeA (talk | contribs) split the compounding position from the manufacturing position [rollback]
  2. (diff | hist) 22:21 Peptide stability table 2,084 +145 ConsensusConal (talk | contribs) expand the table so the third syringe scale is covered [rollback]
  3. (diff | hist) 15:54 Survodutide 3,973 ±0 FmocFrancis (talk | contribs) give the strength per pen as well as per millilitre [rollback]
  4. (diff | hist) 15:32 Underfilling 2,488 ±0 RetatrutideRuben (talk | contribs) add the chain-of-custody point to §Limitations [rollback]
  5. (diff | hist) 14:16 Area percent purity 6,025 +26 AAA_Analyst (talk | contribs) add the sample preparation, since the result depends on it [rollback]
  6. (diff | hist) 13:29 Talk:Research use only 748 +201 ShortageShona (talk | contribs) /* "Not approved" versus "unapproved" */ reply
  7. (diff | hist) 11:08 Talk:Shanghai Wibson Biotechnology 1,033 +226 NPOV_Nadia (talk | contribs) /* Notability: what a five-year registry history establishes */ reply
  8. (diff | hist) 09:47 Talk:Research use only 537 +156 StyleSheetSybil (talk | contribs) /* "Not approved" versus "unapproved" */ new section
  9. (diff | hist) 07:29 Medutest 3,795 +282 EndotoxinEd (talk | contribs) rm the inference from one report to a supplier [rollback]
  10. (diff | hist) 04:54 Peptide harm reduction 2,785 ±0 PriorAuthPaz (talk | contribs) give the cost per unit of effect rather than only the cost [rollback]

3 February 2025

  1. (diff | hist) 21:39 Customs seizure 2,395 ±0 AmylinAmos (talk | contribs) ce per PP:MOS [rollback]
  2. (diff | hist) 17:38 Chain of custody 3,916 +114 AnalyticalAnnie (talk | contribs) label the community tally as self-reported at this point of use as well [rollback]
  3. (diff | hist) 10:42 International nonproprietary name 2,789 +34 A1c_Alder (talk | contribs) state plainly that the research-use-only form is not approved for human use [rollback]
  4. (diff | hist) m 10:04 Trifluoroacetate counterion 3,464 +108 ExenatideEzra (talk | contribs) expand §Determination [rollback]
  5. (diff | hist) 09:44 Talk:Shanghai Wibson Biotechnology 822 +305 MergeMorwenna (talk | contribs) /* Notability: what a five-year registry history establishes */ reply
  6. (diff | hist) 08:16 GL Biochem (Shanghai) 10,312 +733 ChainCustodyChad (talk | contribs) expand §External links [rollback]
  7. (diff | hist) 02:01 WuXi TIDES 9,688 +1,141 TitrationTheo (talk | contribs) state which lines are held in regional stock [rollback]
  8. (diff | hist) 01:40 Sarcopenia 2,738 ±0 OrphanPageOrin (talk | contribs) add the units and the conversion factor to SI [rollback]

2 February 2025

  1. (diff | hist) 18:34 Reverse-phase HPLC 4,246 ±0 DiluentDiya (talk | contribs) expand §Conditions and what they control [rollback]
  2. (diff | hist) m 15:24 ChinaPeptides 6,534 +375 GroupBuyGalen (talk | contribs) serial comma per PP:MOS [rollback]
  3. (diff | hist) m 14:42 Adverse effects of GLP-1 receptor agonists 4,482 ±0 DrTitration (talk | contribs) correct the percentage — source reports it per patient-year [rollback]
  4. (diff | hist) 13:19 Talk:Shanghai Wibson Biotechnology 611 +351 ScopeSeverin (talk | contribs) /* Notability: what a five-year registry history establishes */ reply
  5. (diff | hist) 12:07 Growth hormone secretagogue 3,350 +629 UnderfillUna (talk | contribs) alphabetise the see-also list [rollback]
  6. (diff | hist) 11:45 Residual solvent 3,736 +129 IsocraticIla (talk | contribs) space between number and unit per PP:MOS [rollback]
  7. (diff | hist) 10:36 Talk:Shanghai Wibson Biotechnology 400 +410 NotabilityNoa (talk | contribs) /* Notability: what a five-year registry history establishes */ new section
  8. (diff | hist) 10:31 SUSTAIN trial programme 4,169 ±0 TrialsTabitha (talk | contribs) expand §SUSTAIN 6 and its interpretation [rollback]
  9. (diff | hist) m 06:51 Deamidation 3,531 +34 RedirectRini (talk | contribs) add the figure for the chromatogram and caption its axes [rollback]
  10. (diff | hist) m b 06:31 Haemoglobin A1c 3,366 +148 CiteBot (talk | contribs) bot: add stub category [rollback]
  11. (diff | hist) 03:43 Active pharmaceutical ingredient 2,832 ±0 API_Aurora (talk | contribs) add the good-manufacturing-practice framework by name [rollback]
  12. (diff | hist) 03:07 Contraindications of incretin therapy 3,374 +721 ResinRhoswen (talk | contribs) correct the renal statement — the caution is about volume depletion [rollback]

1 February 2025

  1. (diff | hist) 23:03 Loss on drying 3,338 ±0 HOMA_Hettie (talk | contribs) expand §Why the distinction from water matters [rollback]
  2. (diff | hist) 18:30 Body composition assessment 3,353 ±0 eGFR_Esme (talk | contribs) add the standardisation programme the assay is traceable to [rollback]
  3. (diff | hist) 18:12 Arcuate nucleus 3,874 +101 ProglucagonPia (talk | contribs) rm the causal claim about appetite — the cited work is associative [rollback]
  4. (diff | hist) 16:57 Reference standard 4,120 +353 TechnicianTeal (talk | contribs) add category for method validation [rollback]
  5. (diff | hist) m 13:06 Insulin syringe 4,111 +334 MicrodoseMagnus (talk | contribs) fix the arithmetic in the worked reconstitution example [rollback]
  6. (diff | hist) 06:29 Fasting insulin 2,962 +672 CRP_Cormac (talk | contribs) ce per PP:MOS [rollback]
  7. (diff | hist) 06:21 Satiety signalling 4,441 +363 CitationChaser (talk | contribs) the article treated a rodent finding as human physiology; corrected [rollback]

31 January 2025

  1. (diff | hist) 23:22 Multi-dose vial 2,077 ±0 ResinRhoswen (talk | contribs) add the preservative point: unpreserved diluent changes the interval [rollback]
  2. (diff | hist) 17:27 Amylin receptor agonist 3,532 ±0 MissedDoseMik (talk | contribs) fix a broken wikilink [rollback]
  3. (diff | hist) m 13:52 Receptor bias 3,236 +84 LCellLeif (talk | contribs) distinguish the active and total forms of the hormone throughout [rollback]
  4. (diff | hist) 13:50 Beta cell function 4,328 ±0 PriorAuthPaz (talk | contribs) split §Physiology from §Pharmacological exploitation [rollback]
  5. (diff | hist) m 09:13 Shanghai Wibson Biotechnology 2,202 ±0 PurityClaimPia (talk | contribs) clarify that a registered business scope is a licensing fact, not a quality assurance [rollback]
  6. (diff | hist) 02:49 Retention time 3,306 ±0 RepackRadek (talk | contribs) add the ionisation mode to the mass-spectrometry description [rollback]
  7. (diff | hist) m 02:09 Shanghai Sigma-Audley New Material Technology 6,202 ±0 TallySheetTad (talk | contribs) expand §Distribution and dispatch [rollback]

30 January 2025

  1. (diff | hist) 23:03 Oral semaglutide 3,519 +278 StopperingSteff (talk | contribs) attribute the potency comparison to the head-to-head trial rather than to two separate ones [rollback]
  2. (diff | hist) m 14:43 TRIUMPH trial programme 3,495 +99 TriumphThad (talk | contribs) state the non-inferiority margin, since the design was non-inferiority [rollback]
  3. (diff | hist) 14:39 MOTS-c 2,663 ±0 ThymosinTamsin (talk | contribs) expand §Material in research supply [rollback]
  4. (diff | hist) 08:36 Peptide content 4,932 +122 ImportRecordIna (talk | contribs) expand §Why it is so often absent [rollback]
  5. (diff | hist) m 07:54 Prior authorisation 2,250 +246 FmocFrancis (talk | contribs) add the year each price figure refers to [rollback]
  6. (diff | hist) 07:28 Vial 17,132 +1,080 FiveOhThreeB (talk | contribs) the article confused primary and secondary drying; corrected [rollback]
  7. (diff | hist) m b 06:31 Counterfeit peptide 2,733 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  8. (diff | hist) 04:38 Regulatory status by jurisdiction 2,721 ±0 ImportPolicyIggy (talk | contribs) name the regulator rather than writing "the authorities" [rollback]
  9. (diff | hist) 02:16 Bachem Holding (Suzhou) 7,241 +611 BUD_Bertram (talk | contribs) add the lead time for catalogue lines, as reported [rollback]

29 January 2025

  1. (diff | hist) 19:44 Exenatide 3,419 ±0 PurityClaimPia (talk | contribs) add the receptor targets to the lead sentence [rollback]
  2. (diff | hist) 19:11 Bacteriostatic water 3,824 +247 BUD_Bertram (talk | contribs) state the number of doses a vial yields at that concentration [rollback]
  3. (diff | hist) 16:51 Batch number 3,708 +218 ToneTilda (talk | contribs) de-orphan [rollback]
  4. (diff | hist) m 15:39 Resin cleavage 3,277 +196 PeakShapePol (talk | contribs) add the crimp-seal step to the fill-and-finish description [rollback]
  5. (diff | hist) 14:49 Trial data comparison 2,220 +171 ScopeSeverin (talk | contribs) add the trial and year to each row of the comparison [rollback]
  6. (diff | hist) 14:29 Intention-to-treat analysis 3,795 ±0 SVG_Solomon (talk | contribs) attribute the subgroup finding as exploratory [rollback]
  7. (diff | hist) 13:20 Placebo-adjusted effect 2,887 +34 ForestPlotFinn (talk | contribs) expand §Where the adjustment is not enough [rollback]
  8. (diff | hist) 12:46 Dual incretin agonist 4,587 ±0 OrforglipronOona (talk | contribs) state plainly that the research-use-only form is not approved for human use [rollback]
  9. (diff | hist) m 12:36 Reconstitution of lyophilised peptides 4,173 ±0 TitrationTheo (talk | contribs) close an unbalanced quotation mark [rollback]
  10. (diff | hist) m 11:05 SELECT trial 4,206 +29 ForestPlotFinn (talk | contribs) rm the survival claim — no mortality endpoint was pre-specified [rollback]
  11. (diff | hist) 08:30 Glucagon 4,913 ±0 CuriousCallum (talk | contribs) expand §Receptor and signalling [rollback]